The global aortic valve market is anticipated to grow t a CAGR of 13.1% during the forecast period 2021-2027 owing to the rising prominence of valvular diseases and awareness on valve replacement will propel the growth of the aortic valve market. Moreover, the rise in the adoption of minimally invasive surgeries and industry players are building strategic initiatives like partnerships, collaboration, and joint ventures with hospitals and ambulatory centers to have a competitive edge in the market.

The COVID-19 pandemic has had an adverse impact on the aortic valve market owing to strict lockdown and non-operational hospitals in many countries. There was a decrease in the sale of many products including aortic valves, resulting in less demand. Moreover, there was the temporary closure of manufacturing facilities, constraints in the handling capacity of goods at ports, and extensive financial distress.

Request to get a free sample copy at https://www.vynzresearch.com/healthcare/aortic-valve-market/request-sample

Based on surgery type, minimally invasive surgeries are anticipated to have a significant share during 2021-2027 owing to the rising prominence of transcatheter aortic valve replacement that causes less trauma to the patient and have a speedy recovery. Furthermore, minimally invasive surgeries require a reduced hospital stay and are economically viable.

Europe holds a significant share in the aortic valve market owing to the developed healthcare infrastructure, increased spending on healthcare, rising geriatric population, mounting prevalence of chronic and lifestyle-related diseases in the region. Furthermore, a substantial occurrence of aortic stenosis, the advent of effective treatments, like transcatheter aortic valve replacement (TAVR), and intensifying initiatives to create awareness regarding valve replacement surgeries will propel the growth in the European market.

Edwards Lifesciences Corporation has received Chinese regulatory approval for Edwards SAPIEN 3 transcatheter heart valve, to treat patients suffering from severe, symptomatic aortic stenosis (AS), that are not able to undergo open-heart surgery or for highly risky invasive procedures.

Medtronic plc has received FDA approval and launched in US Evolut PRO+ TAVR system that offers a low delivery profile and added surface area contact between the valve and the native aortic annulus, to further develop valve sealing performance.

The key players operating in the aortic valve industry include Boston Scientific Corporation, LivaNova Plc, Edwards Lifesciences Corporation, Abbott Laboratories, CryoLife Inc., and Medtronic plc.

Source: VynZ Research